Market Closed -
Nasdaq
04:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
0.2252
USD
|
+1.53%
|
|
-13.72%
|
-5.89%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5.363
|
19.27
|
24.02
|
8.254
|
2.867
|
3.416
|
-
|
Enterprise Value (EV)
1 |
5.363
|
19.27
|
24.02
|
8.254
|
2.867
|
3.416
|
3.416
|
P/E ratio
|
-0.19
x
|
-1.34
x
|
-2.11
x
|
-0.6
x
|
-0.13
x
|
-0.29
x
|
-0.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.65
x
|
24.1
x
|
39.1
x
|
18.3
x
|
47.8
x
|
1.52
x
|
0.85
x
|
EV / Revenue
|
6.65
x
|
24.1
x
|
39.1
x
|
18.3
x
|
47.8
x
|
1.52
x
|
0.85
x
|
EV / EBITDA
|
-0.64
x
|
-2.04
x
|
-2.09
x
|
-0.63
x
|
-0.2
x
|
-0.3
x
|
-0.26
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
782
|
3,334
|
4,882
|
4,944
|
11,981
|
15,402
|
-
|
Reference price
2 |
6.860
|
5.780
|
4.920
|
1.670
|
0.2393
|
0.2218
|
0.2218
|
Announcement Date
|
3/19/20
|
3/16/21
|
3/9/22
|
3/14/23
|
4/1/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.806
|
0.799
|
0.614
|
0.45
|
0.06
|
2.25
|
4
|
EBITDA
1 |
-8.393
|
-9.427
|
-11.47
|
-13.19
|
-14.13
|
-11.32
|
-12.95
|
EBIT
1 |
-8.596
|
-9.609
|
-11.69
|
-13.45
|
-14.42
|
-11.69
|
-13.25
|
Operating Margin
|
-1,066.5%
|
-1,202.63%
|
-1,904.23%
|
-2,989.11%
|
-24,028.33%
|
-519.73%
|
-331.25%
|
Earnings before Tax (EBT)
1 |
-13.21
|
-10.15
|
-11
|
-13.41
|
-14.46
|
-13.5
|
-13.25
|
Net income
1 |
-12.96
|
-10.21
|
-11.03
|
-13.57
|
-14.46
|
-11.69
|
-13.25
|
Net margin
|
-1,607.44%
|
-1,277.35%
|
-1,796.58%
|
-3,014.67%
|
-24,091.67%
|
-519.73%
|
-331.25%
|
EPS
2 |
-35.50
|
-4.300
|
-2.330
|
-2.760
|
-1.820
|
-0.7550
|
-0.8500
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/16/21
|
3/9/22
|
3/14/23
|
4/1/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.092
|
0.152
|
0.149
|
0.103
|
0.111
|
0.087
|
0.06
|
-
|
-
|
-
|
1.875
|
0.375
|
-
|
-
|
-
|
EBITDA
1 |
-3.034
|
-2.913
|
-3.262
|
-3.367
|
-3.421
|
-3.138
|
-3.731
|
-3.591
|
-3.631
|
-3.174
|
-1.553
|
-2.832
|
-3.463
|
-3.474
|
-
|
EBIT
1 |
-3.091
|
-2.968
|
-3.321
|
-3.436
|
-3.49
|
-3.204
|
-3.8
|
-3.667
|
-3.703
|
-3.247
|
-1.646
|
-2.925
|
-3.556
|
-3.567
|
-
|
Operating Margin
|
-3,359.78%
|
-1,952.63%
|
-2,228.86%
|
-3,335.92%
|
-3,144.14%
|
-3,682.76%
|
-6,333.33%
|
-
|
-
|
-
|
-87.79%
|
-780%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.392
|
-2.969
|
-3.322
|
-3.434
|
-3.48
|
-3.174
|
-3.782
|
-3.681
|
-3.726
|
-3.266
|
-2
|
-3.5
|
-4
|
-4
|
-
|
Net income
1 |
-2.398
|
-2.98
|
-3.331
|
-3.443
|
-3.489
|
-3.303
|
-3.782
|
-3.681
|
-3.726
|
-3.266
|
-1.646
|
-2.925
|
-3.556
|
-3.567
|
-
|
Net margin
|
-2,606.52%
|
-1,960.53%
|
-2,235.57%
|
-3,342.72%
|
-3,143.24%
|
-3,796.55%
|
-6,303.33%
|
-
|
-
|
-
|
-87.79%
|
-780%
|
-
|
-
|
-
|
EPS
2 |
-0.4900
|
-0.6100
|
-0.6800
|
-0.7000
|
-0.7100
|
-0.6700
|
-0.7600
|
-0.6400
|
-0.4100
|
-0.1200
|
-0.1100
|
-0.1900
|
-0.2250
|
-0.2250
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/9/22
|
5/11/22
|
8/10/22
|
11/14/22
|
3/14/23
|
5/10/23
|
8/14/23
|
11/14/23
|
4/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.06
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
7.57%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/16/21
|
3/9/22
|
3/14/23
|
4/1/24
|
-
|
-
|
Last Close Price
0.2218
USD Average target price
0.5
USD Spread / Average Target +125.43% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.89% | 3.42M | | +1.77% | 42.75B | | +47.70% | 41.61B | | +12.24% | 41.34B | | -8.83% | 26.59B | | +7.44% | 25.49B | | -23.01% | 18.12B | | +30.56% | 12.24B | | -1.82% | 11.76B | | +8.35% | 11B |
Other Biotechnology & Medical Research
|